<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03877731</url>
  </required_header>
  <id_info>
    <org_study_id>HCMP-MV151</org_study_id>
    <nct_id>NCT03877731</nct_id>
  </id_info>
  <brief_title>Mitral Valve in Hypertrophic Cardiomyopathy</brief_title>
  <official_title>Role of Mitral Valve in the Obstruction of Left Ventricular Outflow Tract in Patients With Hypertrophic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomsk National Research Medical Center of the Russian Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomsk National Research Medical Center of the Russian Academy of Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the role of mitral valve apparatus in the development
      of outflow tract obstruction in patients with hypertrophic cardiomyopathy and to identify the
      best surgical treatment modality to relieve outflow tract obstruction in such patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well-known that mitral valve plays an important role in the development of left
      ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy. In order
      to further investigate this phenomenon, the following study aims to compare mitral valve
      geometry indices, as assessed by transthoracic echocardiography, two- and three-dimentional
      transesophageal echocardiography and mitral valve quantification analysis, and papillary
      musles' function, as assessed by 2D speckle tracking imaging, in patients with hypertrophic
      obstructive cardiomyopathy, patients with arterial hypertension and left ventricular
      hypertrophy and people without structural heart disease. This will provide information on the
      geometric characteristics of mitral valve that predispose to the development of obstruction.
      Futhermore, patients with hypertrophic obstructive cardiomyopathy that are eligible for the
      surgical relief of obstruction will be randomised into four groups according to the modality
      of intervention. These groups are as follows: 1) isolated extended septal myectomy; 2)
      extended septal myectomy + edge to edge mitral valve repair; 3) extended septal myectomy +
      posterior lealfet sliding plasty; 4) extended septal myectomy + secondary chordae
      transection. After surgery, said indices will be reassessed and the degree of outflow tract
      obstruction relief noted, in order to elicit which geometrical changes are produced by each
      type of intervention. Patients will be followed long-term, up to 5 years, in order to define
      whether the addition of the intervention on mitral valve helps abolish the residual gradient
      more effectively, and whether it translates into any survival benefit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2006</start_date>
  <completion_date type="Actual">September 1, 2019</completion_date>
  <primary_completion_date type="Actual">May 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>patients' survival without hospital admissions due to the recurring sympthoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual left vetricular outflow tract gradient</measure>
    <time_frame>5 years</time_frame>
    <description>left ventricular outflow tract gradient measured by continuous doppler from 5-chamber apical view</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral regurgitation</measure>
    <time_frame>5 years</time_frame>
    <description>degree of mitral regurgitation assessed by color doppler, regurgitant volume measured using PISA method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Papillary muscles' funcion</measure>
    <time_frame>5 years</time_frame>
    <description>papillary muscles' strain and strain rate assessed by 2D speckle tracking imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitral valve geometry</measure>
    <time_frame>10 days</time_frame>
    <description>indices of mitral valve geometry assessed by 2D transthoracic and transesophageal echocardiography and mitral valve quantification analysis</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hypertrophic Obstructive Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>hypertrophic cariomyopathy, isolated septal myectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with hypertrophic obstructive cardiomyopathy who will undergo isolated septal myectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertrophic cariomyopathy, septal myectomy + edge-to-edge</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and edge-to-edge mitral valve repair (O. Alfieri technique)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertrophic cariomyopathy, septal myectomy + sliding plasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and posterior leaflet sliding plasty ( A. Carpentier technique)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypertrophic cariomyopathy, septal myectomy + chordae</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hypertrophic obstructive cardiomyopathy who will undergo septal myectomy and secondary chordae transection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arterial hypertension + left ventricular hypertrophy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with arterial hypertension with left ventricular hypertrophy whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients without structural heart disease whose mitral valve geometry and papillary muscles' function will be compared to those of the patients with hypertrophic cardiomyopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>isolated septal myectomy</intervention_name>
    <arm_group_label>hypertrophic cariomyopathy, isolated septal myectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>septal myectomy + edge-to-edge mitral valve repair</intervention_name>
    <arm_group_label>hypertrophic cariomyopathy, septal myectomy + edge-to-edge</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>septal myectomy + posterior leaflet sliding plasty</intervention_name>
    <arm_group_label>hypertrophic cariomyopathy, septal myectomy + sliding plasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>septal myectomy + secondary chordae transection</intervention_name>
    <arm_group_label>hypertrophic cariomyopathy, septal myectomy + chordae</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Signed informed consent to participate in the study

          -  For patients with hypertrophic cardiomyopathy only: resting or latent peak left
             ventricular outflow tract gradient &gt;50 mmHg, NYHA class III-IV

          -  For patients with arterial hypertension only: hystory of arterial pressure increase
             &gt;140/90 mmHg, increased left vantricular wall thickness (&gt;10 mm) and myocardial mass
             indexed to BSA (&gt;95 g/m2 for women and &gt;115 g/m2 for men), as assessed by 2D
             transthoracic echocardiography

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Persistent form of atrial fibrillation

          -  Intrinsic mitral or aortic valve disease

          -  Coronary artery disease

          -  Reduced left ventricular ejection fraction

          -  For control group only: presence of any structural heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Pavlyukova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiology Research Institute, Tomsk NRMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology research institute, National Research Medical Center of the Russian Academy of Sciences</name>
      <address>
        <city>Tomsk</city>
        <zip>634012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypertrophic cardiomyopathy, mitral valve, echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

